Consensus best practice pathway of the UK Scleroderma Study Group: Digital vasculopathy in systemic sclerosis

Rheumatology (United Kingdom)

Volumn 54, Issue 11, 2015, Pages 2015-2024

  Hughes, Michael ^a   Ong, Voon H ^b   Anderson, Marina E ^c   Hall, Frances ^d   Moinzadeh, Pia ^e   Griffiths, Bridget ^f   Baildam, Eileen ^g   Denton, Christopher P ^b   Herrick, Ariane L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF COLOGNE   (Germany)

^f FREEMAN HOSPITAL   (United Kingdom)

^g ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Critical digital ischaemia; Digital ulcer; Digital vasculopathy; Raynaud's phenomenon; Scleroderma; Systemic sclerosis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCLOXACILLIN; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; SEROTONIN UPTAKE INHIBITOR; VASODILATOR AGENT;

ALGORITHM; ALTERNATIVE MEDICINE; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; CALCINOSIS; CLINICAL ASSESSMENT; DEBRIDEMENT; DIGITAL ISCHEMIA; DISABILITY; EVIDENCE BASED PRACTICE; FINGER ULCER; HUMAN; ISCHEMIA; LIFESTYLE; OSTEOMYELITIS; PAIN; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRESCRIPTION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SMOKING CESSATION; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; UNITED KINGDOM; VASCULAR DISEASE; WOUND CARE;

EID: 84946741528     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev201     Document Type: Article

References (43)

1. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62
2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
3. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011;6:509-37.
4. Kowal-Bielecka O, Landewe R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
5. Herrick AL. Secondary Raynaud's phenomenon. Clin Evid 2008;9:1125.
6. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001;357:2042-8.
7. Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 2010;62:2595-604.
8. Meier FM, Frommer KW, Dinser R et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
9. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
10. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000;155:1-15.
11. Thompson AE, Shea B, Welch V, Fenton D, Pope JE. Calcium channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
12. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology 2005;44:145-50.
13. Ennis H, Anderson ME, Wilkinson J, Herrick AL. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2014;(1):CD002069.
14. Dziadzio M, Denton CP, Smith R et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial. Arthritis Rheum 1999;42:2646-55.
15. Coleiro B, Marshall SE, Denton CP et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038-43.
16. Harding SE, Tingey PC, Pope J et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;(2):CD000956.
17. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother 2006;40:1998-2002.
18. Gliddon AE, DoréCJ, Black CM et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56:3837-46.
19. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
20. Shenoy PD, Kumar S, Jha LK et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology 2010;49:2420-8.
21. Herrick AL, van den Hoogen F, Gabrielli Aet al. Modifiedrelease sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.
22. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008;35:1801-8.
23. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. Ann Intern Med 1994;120:199-206.
24. Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;(2):CD000953.
25. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000;132:425-34.
26. Roustit M, Blaise S, Allanore Y et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013;72:1696-9.
27. Tiev KP, Diot E, Clerson P et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol 2009;36:1470-6.
28. Khimdas S, Harding S, Bonner A et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group Registry. Arthritis Care Res 2011:63;142-9.
29. Hachulla E, Clerson P, Launay D et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34:2423-30.
30. Mouthon L, Mestre-Stanilas C, Berezne A et al. Impact of digital ulcers on disability and health related quality of life in SSc. Ann Rheum Dis 2010;69:214-7.
31. Ennis H, Vail A, Wragg E et al. A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol 2013;42:483-6.
32. Berezne A, Seror R, Morell-Dubois S et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res 2011;63:277-85.
33. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002;46:3312-6.
34. Giuggioli D, Manfredi A, Colaci M, Lumetti F, Ferri C. Scleroderma digital ulcers complicated by infection with fecal pathogens. Arthritis Care Res 2012;64:295-7.
35. Zhou A, Muir L, Harris J, Herrick A. The impact of magnetic resonance (MR) imaging in early diagnosis of hand osteomyelitis in patients with systemic sclerosis. Clin Exp Rheumatol 2014;32(6 Suppl 86):S-232.
36. Bruecker CS, Becker MO, Kroencke T et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8.
37. Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 2013;65:1460-71.
38. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
39. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, doubleblind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
40. Hartzell TL, Makhni EC, Sampson C. Long term results of periarterial sympathectomy. J Hand Surg 2009;34A: 1454-60.
41. O'Brien BM, Kumar PAV, Mellow CG, Oliver TV. Radical microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma. J Hand Surg Eur 1992;17:447-52.
42. Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008;67:120-3.
43. Kim JS, Kim J, Choi D et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010;3:332-9.